文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Qualitative evaluation of survey questions to assess treatment preference for daily oral or long‑acting injectable antiretroviral therapy among people living with HIV.

作者信息

Garris Cindy, Kolobova Irina, Chounta Vasiliki, Díaz De Santiago Alberto, Dretler Robin, Singh Tulika, Sinclair Gary

机构信息

ViiV Healthcare, Durham, NC, United States of America.

ViiV Healthcare, Brentford, United Kingdom.

出版信息

PLoS One. 2024 Dec 27;19(12):e0309588. doi: 10.1371/journal.pone.0309588. eCollection 2024.


DOI:10.1371/journal.pone.0309588
PMID:39729497
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11676866/
Abstract

Treatment of HIV has historically required taking daily oral antiretroviral therapy (ART). A recent alternative to daily oral ART is long-acting injectable ART with cabotegravir plus rilpivirine, administered monthly or every 2 months. The purpose of this qualitative study was to evaluate the concept relevance and interpretability of five previously developed questions: one treatment preference question and four questions designed to assess how the emotional burden associated with HIV treatment impacts treatment preferences. Thirty adults in the United States currently receiving HIV treatment were enrolled in a cross-sectional study involving one-on-one concept confirmation and cognitive debriefing interviews. Concept confirmation interviews included topics, questions, and probes designed to elicit information about the emotional burden of HIV and current perceptions of a participant's treatment regimen. Cognitive debriefing assessed the relevance and clarity of instructions, questions, response options, and recall periods. Transcripts were analyzed with MAXQDA. Mean age of participants was 49 years (range: 29-68), with 60% being male and 40% female. Racial demographics included Blacks (40%), Whites (40%), and other (20%). During concept confirmation, participants endorsed concepts relevant to HIV treatment preference: fear of disclosure of HIV status (47%), forgetting to take daily oral medication (40%), and current treatment regimen as a bothersome daily reminder of HIV status (40%). During cognitive debriefing, participants interpreted the instructions, question, response options, and recall periods as intended for the treatment preference question. Additionally, participants confirmed that the preference question's response options were appropriate and relevant to the experiences of people living with HIV. Participants also consistently interpreted the questions related to fear of disclosure of HIV status, anxiety associated with forgetting to take HIV medication, and HIV medication being an uncomfortable reminder of HIV status; however, participants provided variable responses to the question designed to assess treatment ease of use. These results support the concept relevance and interpretability of the single treatment preference question and three of the four emotional well-being questions among adults living with HIV.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d41/11676866/8ff28691ef21/pone.0309588.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d41/11676866/957092adf900/pone.0309588.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d41/11676866/732808089ae2/pone.0309588.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d41/11676866/8ff28691ef21/pone.0309588.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d41/11676866/957092adf900/pone.0309588.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d41/11676866/732808089ae2/pone.0309588.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d41/11676866/8ff28691ef21/pone.0309588.g003.jpg

相似文献

[1]
Qualitative evaluation of survey questions to assess treatment preference for daily oral or long‑acting injectable antiretroviral therapy among people living with HIV.

PLoS One. 2024-12-27

[2]
Brief Report: Stated Preferences for Long-Acting Injectable ART Among Mobile Men Living With HIV in Malawi: A Qualitative Study.

J Acquir Immune Defic Syndr. 2024-12-15

[3]
Long-acting injectable antiretroviral treatment: experiences of people with HIV and their healthcare providers in Uganda.

BMC Infect Dis. 2024-8-28

[4]
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.

PLoS One. 2018-1-5

[5]
Willingness to Switch to Long-Acting Injectable Cabotegravir and Rilpivirine Every 2 Months for People Living with HIV in Nanjing, China.

AIDS Res Hum Retroviruses. 2025-2

[6]
Interest in and Preference for Long-acting Injectable Antiretroviral Therapy in the Era of Approved Cabotegravir/Rilpivirine Among Reproductive-aged Women in the US South.

Clin Infect Dis. 2025-2-5

[7]
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).

Patient. 2021-11

[8]
Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study.

AIDS Behav. 2025-1

[9]
Potential healthcare resource use and associated costs of every 2 month injectable cabotegravir plus rilpivirine long-acting regimen implementation in the Spanish National Healthcare System compared to daily oral HIV treatments.

BMC Infect Dis. 2024-8-2

[10]
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.

Lancet HIV. 2025-3

引用本文的文献

[1]
"Injectable ARVs will give me peace" women's acceptability of injectable antiretroviral therapy in prevention of HIV vertical transmission in Uganda.

Sci Rep. 2025-7-16

本文引用的文献

[1]
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.

Lancet HIV. 2023-9

[2]
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.

Clin Infect Dis. 2023-5-3

[3]
Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV.

Qual Life Res. 2023-2

[4]
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).

Patient. 2021-11

[5]
Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries.

Sex Transm Infect. 2021-12

[6]
Physical, Emotional, and Psychosocial Challenges Associated with Daily Dosing of HIV Medications and Their Impact on Indicators of Quality of Life: Findings from the Positive Perspectives Study.

AIDS Behav. 2021-3

[7]
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.

AIDS Behav. 2020-12

[8]
Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials.

AIDS Behav. 2020-12

[9]
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.

PLoS One. 2018-1-5

[10]
Forgetting to remember or remembering to forget: a study of the recall period length in health care survey questions.

J Health Econ. 2014-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索